Lazcluze demonstrated significant CNS activity, regardless of T790M status, in treating intracranial and leptomeningeal ...
Moreover, the impressive intracranial objective response rate (iORR) of 71% in the Phase 2 study indicates that the Bria-IMT + CPI regimen could provide meaningful benefits to a significant ...
as monotherapy and in combination with PD-1 inhibitor ti 83% intracranial objective response rate (iORR) with Bria-IMTâ„¢ in heavily pretreated advanced breast cancer patients with CNS ...